Fabrication, assessment, and optimization of alendronate sodium nanoemulsion-based injectable in-situ gel formulation for management of osteoporosis

References

• Abdelbary A, Salem HF, Khallaf RA, et al. (2017). Mucoadhesive niosomal in situ gel for ocular tissue targeting: in vitro and in vivo evaluation of lomefloxacin hydrochloride. Pharm Dev Technol 22:1–9.
   PubMed Web of Science ®Google Scholar
• Alhakamy NA, Hosny KM, Aldryhim AY, et al. (2022). Development and optimization of ofloxacin as solid lipid nanoparticles for enhancement of its ocular activity. J Drug Deliv Sci Technol 72:103373.
   Web of Science ®Google Scholar
• Ali SA, Sindi AM, Mair YH, et al. (2021). Oral gel loaded by ethotransfersomes of antifungal drug for oral thrush: preparation, characterization, and assessment of antifungal activity. J Drug Deliv Sci Technol 66:102841.
   Web of Science ®Google Scholar
• Alkhalidi HM, Naguib GH, Kurakula M, et al. (2018). In vitro and preclinical assessment of factorial design based nanoethosomal transdermal film formulation of mefenamic acid to overcome barriers to its use in relieving pain and inflammation. J Drug Deliv Sci Technol 48:450–6.
   Web of Science ®Google Scholar
• Bauer DC, Black D, Ensrud K, et al. (2000). Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517–25.
   PubMed Web of Science ®Google Scholar
• Bone HG, Hosking D, Devogelaer J, Alendronate Phase III Osteoporosis Treatment Study Group, et al. (2004). Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–99.
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon D, et al. (2007). Incidence and economic burden or osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–75.
   PubMed Web of Science ®Google Scholar
• Camargo JA, Sapin A, Nouvel C, et al. (2013). Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterization. Drug Dev Ind Pharm 39:146–55.
   PubMed Web of Science ®Google Scholar
• Chenite A, Chaput C, Wang D, et al. (2000). Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 21:2155–61.
   PubMed Web of Science ®Google Scholar
• Dai ZW, Zou XH, Chen GQ. (2009). Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) as an injectable implant system for prevention of post-surgical tissue adhesion. Biomaterials 30:3075–83.
   PubMed Web of Science ®Google Scholar
• Dimatteo R, Darling NJ, Segura T. (2018). In situ forming injectable hydrogels for drug delivery and wound repair. Adv Drug Deliv Rev 127:167–84.
   PubMed Web of Science ®Google Scholar
• Hassan AH, Hosny KM, Murshid ZA, et al. (2015). Depot injectable biodegradable nanoparticles loaded with recombinant human bone morphogenetic protein-2: preparation, characterization, and in vivo evaluation. Drug Des Dev Ther 9:3599–606.
   PubMed Web of Science ®Google Scholar
• Hassan AH, Hosny KM, Murshid ZA, et al. (2016). Controlled release of injectable liposomal in situ gel loaded with recombinant human bone morphogenetic protein-2 for the repair of alveolar bone clefts in rabbits. J Liposome Res 26:148–55.
   PubMed Web of Science ®Google Scholar
• Hatefi A, Amsden B. (2002). Biodegradable injectable in situ forming drug delivery systems. J Controlled Release 80:9–28.
   PubMed Web of Science ®Google Scholar
• Helgeson ME, Moran SE, An HZ, Doyle PS. (2012). Mesoporous organohydrogels from thermogelling photocrosslinkable nanoemulsions. Nat Mater 11:344–52.
   PubMed Web of Science ®Google Scholar
• Hettiaratchi MH, Schudel A, Rouse T, et al. (2018). A rapid method for determining protein diffusion through hydrogels for regenerative medicine applications. APL Bioeng 2:026110.
   PubMed Web of Science ®Google Scholar
• Hoshino T, Azuma M, Yamada Y, et al. (2019). Measurement of the water content in semi-solid formulations used to treat pressure ulcers and evaluation of their water absorption characteristics. Chem Pharm Bull (Tokyo) 67:929–34.
   PubMed Web of Science ®Google Scholar
• Hosny K, Asfour H, Rizg W, et al. (2021b). Formulation, optimization, and evaluation of oregano oil nanoemulsions for the treatment of infections due to oral microbiota. Int J Nanomed 16:5465–78.
   PubMed Web of Science ®Google Scholar
• Hosny KM, Alhakamy NA, Sindi AM, et al. (2020). Coconut oil nanoemulsion loaded with a statin hypolipidemic drug for management of burns: formulation and in vivo evaluation. Pharmaceutics 12:1061.
   PubMed Web of Science ®Google Scholar
• Hosny KM, Khallaf RA, Asfour HZ, et al. (2021a). Development and optimization of cinnamon oil nanoemulgel for enhancement of solubility and evaluation of antibacterial, antifungal and analgesic effects against oral microbiota. Pharmaceutics 13:1008.
   PubMed Web of Science ®Google Scholar
• Hosny KM, Osama A, Al-abdaly R. (2013). Enteric-coated alendronate sodium nanoliposomes: a novel formulation to overcome barriers for the treatment of osteoporosis. Expert Opin Drug Deliv 10:741–6.
   PubMed Web of Science ®Google Scholar
• Hosny KM, Sindi AM, Alkhalidi HM, et al. (2021c). Development of omega-3 loxoprofen-loaded nanoemulsion to limit the side effect associated with NSAIDs in treatment of tooth pain. Drug Deliv 28:741–751.
   PubMed Web of Science ®Google Scholar
• Hosny KM. (2016). Alendronate sodium as enteric coated solid lipid nanoparticles; preparation, optimization, and in vivo evaluation to enhance its oral bioavailability. Plos One 11:e0154926.
   PubMed Web of Science ®Google Scholar
• Hussein RM, Kandeil MA, Mohammed NA, Khallaf RA. (2022). Evaluation of the hepatoprotective effect of curcumin-loaded solid lipid nanoparticles against paracetamol overdose toxicity: Role of inducible nitric oxide synthase. J Liposome Res 8:1–11.
   Google Scholar
• Kempe S, M€ader K. (2012). In situ forming implants d an attractive formulation principle for parenteral depot formulations. J Control Release 161:668–79.
   PubMed Web of Science ®Google Scholar
• Kranz H, Brazeau GA, Napaporn J, et al. (2001). Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int J Pharm 212:11–8.
   PubMed Web of Science ®Google Scholar
• Packhaeuser CB, Schnieders J, Oster CG, Kissel T. (2004). In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 58:445–55.
   PubMed Web of Science ®Google Scholar
• Pathak S, Tripathi SK, Pachouri C, Pandey A. (2022). Encapsulation of alendronate in chitosan based polymeric nanoparticles for effective management of osteoporosis – development to release kinetic study. Int J Med Nano Res 9:036.
   Google Scholar
• Peters ML, Leonard M, Licata AA. (2001). Role of alendronate and risedronate in preventing and treating osteoporosis. Cleve Clin J Med 68:945–51.
   PubMed Web of Science ®Google Scholar
• Raisz LG. (2005). Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115:3318–25.
   PubMed Web of Science ®Google Scholar
• Rizg WY, Hosny KM, Elgebaly SS, et al. (2021). Preparation and optimization of garlic oil/apple cider vinegar nanoemulsion loaded with minoxidil to treat alopecia. Pharmaceutics 13:2150.
   PubMed Web of Science ®Google Scholar
• Salem HF, Ali AA, Rabea YK, et al. (2022). Glycerosomal thermosensitive in situ gel of duloxetine HCl as a novel nanoplatform for rectal delivery: in vitro optimization and in vivo appraisal. Drug Deliv Transl Res 12:3083–3103.
   PubMed Web of Science ®Google Scholar
• Salem HF, El-Menshawe SF, Khallaf RA, et al. (2020). A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension: optimization using Box-Benkhen design, in vitro and in vivo characterization. Drug Deliv Transl Res 10:227–40.
   PubMed Web of Science ®Google Scholar
• Salem HF, Nafady MM, Ewees MGE, et al. (2022). Rosuvastatin calcium-based novel nanocubic vesicles capped with silver nanoparticles-loaded hydrogel for wound healing management: optimization employing Box-Behnken design: in vitro and in vivo assessment. J Liposome Res 32:45–61.
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Bone HG, Crepaldi G, et al. (2000). Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12:1–12.
   PubMedGoogle Scholar
• Srichan T, Phaechamud T. (2017). Designing solvent exchange-induced in situ forming gel from aqueous insoluble polymers as matrix base for periodontitis treatment. AAPS PharmSciTech 18:194–201.
   PubMed Web of Science ®Google Scholar
• Tadrous M, Mamdani MM, Juurlink DN, et al. (2014). Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis reply to Pazianas and Abrahamsen. Osteoporos Int 25:2671–2.
   PubMed Web of Science ®Google Scholar
• Vintiloiu A, Leroux J-C. (2008). Organogels and their use in drug delivery: a review. J Control Release 125:179–92.
   PubMed Web of Science ®Google Scholar
• Wright N, Looker A, Saag K, et al. (2014). The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29:2520–6.
   PubMed Web of Science ®Google Scholar
• Yang Q, Owusu-Ababio G. (2000). Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug Dev Ind Pharm 26:61–70.
   PubMed Web of Science ®Google Scholar
• Zhang T, Luo J, Peng Q, et al. (2019). Injectable and biodegradable phospholipid-based phase separation gel for sustained delivery of insulin. Colloids Surf B Biointerfaces 176:194–201.
   PubMed Web of Science ®Google Scholar